Objectives: The aim of this study was to describe the rates and predictors of discontinuing first-line antiretroviral therapy in the different eras of treatment over a nearly 20 year period initiated in British Columbia between 1992 and 2010.
Introduction
HIV is a chronic disease that requires life-long therapy and the prognosis of HIV-infected patients starting highly active antiretroviral therapy (HAART) greatly depends on treatment optimization. 1 -3 To better understand the determinants of treatment changes over time it is important to optimize the initial HAART regimen and evaluate trends in the incidence of discontinuation (stopping or switching of initial treatment). Several studies analysing rates of discontinuation reported that a high percentage of patients (40% -60%) underwent discontinuation of their initial regimen within the first year of treatment. 4 -7 Over recent years HAART strategies have evolved dramatically, offering high efficacy, less toxicity and reduced pill burden and dosing frequency. 8 Accordingly, some studies found improvements in virological and immunological outcomes and pointed to time trends towards lower rates of discontinuation. 9 -11 A recent study reported that the risk of multiple treatment modifications (three or more changes in any of the antiretroviral components in the regimen) had decreased over time. 12 However, no studies have found evidence of a significant difference in the rate of discontinuation of the first antiretroviral therapy (ART) (discontinuation for any reason) according to calendar period of starting therapy. 12 -15 It is possible that time period length and/or number of patients included in those studies were not big enough to find a significant difference in the rate of discontinuation, so studies analysing these different eras of treatment are still lacking. Therefore, the aim of this study was to describe the rates and predictors of discontinuing first-line ART in the different eras of treatment over a nearly 20 year period initiated in British Columbia between 1992 and 2010.
hospital or clinic in British Columbia, Canada, were centralized and analysed at the British Columbia Centre for Excellence in HIV/AIDS. Demographic, clinical and laboratory data and information on therapy were collected for all participants. Study was restricted to patients with complete information on age, gender, baseline CD4 and viral load in the HAART era.
The primary factor of interest in this population-based retrospective cohort study was the era of starting ART, grouped as: pre-HAART (September 1992 -May 1996); early HAART (June 1996 to December 2000); mid-HAART (January 2001 to December 2005) and late HAART (January 2006 to December 2010). Other covariates of interest included age, gender, detection of hepatitis C virus (HCV) antibodies on at least one occasion during follow-up, baseline CD4 cell count and plasma HIV RNA (copies/mL), risk group, ethnicity, adherence, AIDS status and type of first ART regimen started [one or two nucleoside reverse transcriptase inhibitors (NRTIs), two NRTIs +one non-nucleoside reverse transcriptase inhibitor (NNRTI), two NRTIs +unboosted or boosted protease inhibitor (PI) or another regimen with three or more antiretrovirals]. Measurement of exposure to ART was obtained by prescription refills. Medication adherence, estimated based on antiretroviral prescription refill data during the first year after starting therapy, was calculated by dividing the number of days of medication dispensed by the number of days of follow-up, expressed as a percentage.
We investigated the time from ART initiation to discontinuation of the first ART within 3 years of starting therapy. Discontinuation was categorized as either a stop (defined as stopping all drugs in a regimen for .6 months) or a switch (changing any of the antiretroviral components, not the formulation, in the regimen). If a patient was virologically suppressed (defined as the two most recent plasma HIV RNA measurements ,50 copies/mL within 6 months) prior to discontinuation, it was considered a discontinuation 'probably' due to a tolerability issue, while those not suppressed were considered as having discontinuation due to virological failure. For the latter purpose only patients from the mid-HAART and late HAART eras were analysed because virological suppression data (plasma HIV RNA ,50 copies/mL) were not available in the pre-HAART and early HAART eras.
The main objective was to compare the rate of discontinuation according to era of ART initiation. Follow-up of the patients who did not stop or switch was censored at the death date, date of moving out of British Columbia, date of entering a placebo trial, date of starting supervised therapy interruption, 30 September 2011 (study end date) or 3 years from ART start date, whichever came first.
Statistical analysis
Comparisons across eras were carried out using the x 2 test or Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Kaplan-Meier methods were used to graphically display the probability of discontinuing regimen after starting ART. Weibull survival analysis was used to model the era of treatment and its association with time to discontinuation. Variables that were significant at P, 0.05 in the unadjusted analyses were candidates for inclusion in the multivariate model. A confounder model was fitted for era using the methods of Maldonado and Greenland. 16 All analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC, USA). 
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Results
A total of 7901 patients were included in the study. Table 1 , where all characteristics were statistically different (P, 0.001). Due to the missing values for ethnicity, risk status and HCV, these variables were not included in the statistical model and are only explored in Table 1 . All analyses involving viral load characteristics were limited to the HAART eras (n¼6046), because in the pre-HAART era (n ¼ 1855) viral loads were not available in most patients, and comparisons of discontinuation based on virological suppression were limited to the mid-HAART and late HAART eras (n¼3640).
Overall, 5490 (69.5%) patients discontinued therapy during follow-up, of whom 3659 (66.6%) were switches and 1831 (33.4%) were stops. The probability of discontinuation at 12, Discontinuation rates in relation to the ART regimen showed that two NRTIs + NNRTI had a lower risk of discontinuation than two NRTIs + boosted or unboosted PI, or other combinations (P, 0.001) (Figure 1c ). In the mid-HAART and late HAART eras, 2119 patients (58.2%) discontinued therapy, of whom 1558 (73.5%) were switches and 561 (26.5%) were stops. Of these mid-HAART and late HAART era discontinuations, 1377 (65.0%) were not virologically suppressed (virological failure switch) at the time of discontinuation and 742 (35.0%) were virologically suppressed (probably a tolerability issue). The probability of discontinuation due to virological failure was greater than discontinuation due to tolerability issues through 3 years of follow-up (0.33 versus 0.13 at 12 months and 0.43 versus 0.37 at 36 months) (Figure 1d ).
During the HAART eras, 3903 (64.6%) patients discontinued therapy, of whom 2628 (67.3%) were switches and 1275 (32.7%) were stops. In unadjusted analysis, most of the variables included were associated with switching or stopping ( Table 2 ). However, in the adjusted model variables associated with switching or stopping were earlier treatment era [mid-HAART (adjusted hazard ratio 1.01, 95% CI 0.94 -1.09) and late HAART (adjusted hazard ratio 0.61, 95% CI 0.56 -0.66) compared with the early HAART], female gender (adjusted hazard ratio 1.23, 95% CI 1.14 -1. Temporal trends in the discontinuation of first-line antiretroviral therapy 2203 JAC that two NRTIs + NNRTI had a lower risk of discontinuation than two NRTIs + boosted or unboosted PI, or other combinations (P,0.001) (Figure 2b ).
Again, in the unadjusted model, most of the variables included were associated with switching or stopping. However, in the adjusted model the variables associated with discontinuation Rates of discontinuation of first-line therapy depending on ART regimen. The probability of discontinuation of first-line therapy up to 36 months is indicated by the dotted line for the two NRTIs +NNRTI, the dashed line for the two NRTIs +boosted PI, the continuous black line for the two NRTIs +unboosted PI and the continuous grey line for the other combinations. (d) Discontinuation was mainly driven by virological failure (viral load not suppressed at time of discontinuation), mostly during the first year; however, tolerability issues (viral load suppressed at time of discontinuation) increased to a similar level over the third year. The continuous line represents the overall probability of discontinuation, the dashed line represents the probability of discontinuation due to tolerability issues and the dotted line represents the probability of discontinuation due to virological failure of first-line therapy initiated between 2001 and 2010.
Temporal trends in the discontinuation of first-line antiretroviral therapy 2205 JAC or other regimens (adjusted hazard ratio 2.58, 95% CI 1.96-3.39) compared with two NRTIs+ NNRTI (Table 3) .
In order to determine whether not excluding pregnant women had an effect on the results, we conducted a sensitivity analysis. We assumed that women whose ART regimen contained zidovudine and lasted ,1 year and who had a CD4 count .350 cells/mm 3 at therapy initiation had been taking ART solely for the prevention of mother-to-child transmission of HIV. We found 133 women who met these criteria. However, when these women were excluded from the analysis, the results were unchanged.
Discussion
In this study we show that rates of first-line therapy discontinuation over a nearly 20 year period decreased over time. However, the probability of stopping and/or switching to a second-line regimen was considerable even with access to the latest era of antiretrovirals and drug combinations.
The decreases in rates of discontinuation found in this study challenge previous findings, where similar studies reported unchanging discontinuation rates according to study period. 12 -15,17 It is possible that the study duration, in some cases ,5 years, and/or the low number of patients used in these studies could explain why a decrease in discontinuation was not found previously. In fact, there is one study, analysing 1189 patients between 1997 and 2007, that found a decreasing risk of multiple treatment modifications (three or more) over time but concluded that first treatment discontinuation was comparable according to calendar period. 12 In comparison, our study of 7901 patients over a nearly 20 year period showed a significant decrease in the rates of treatment discontinuation. Moreover, some studies found that discontinuation because of intolerance and/or toxicity was decreasing over time while discontinuation because of therapy simplification was increasing over time. This in part could explain the absence of an overall decreasing trend globally. 12 -15 With the increased availability of newer drugs, drug classes and multidrug-containing regimens, and those with better tolerability, dosing and resistance profiles, the individualization of treatment has led to improved virological and immunological outcomes for HIV-infected patients. This may be one of the primary factors associated with the decrease in discontinuation observed in our study, given the study's duration and geographic region.
All analyses were repeated by defining failure as .500 copies/mL for consistency between the different eras and the results were consistent (data not shown). Overall, the rates of discontinuation of first-line therapy found in our study are slightly higher than those in some previous studies. 17 -21 Injection drug use and Gonzalez-Serna et al.
HCV/HIV co-infection have been associated with decreased adherence and increased treatment discontinuation. 22, 23 In the adjusted analysis, the risk of discontinuing first-line ART was positively correlated with younger age, female gender, lower CD4 counts, low ART adherence and starting treatment in an earlier era. Several studies have reported that younger HIV patients and those with lower CD4 counts have poorer adherence and lower rates of virological response. 6, 14, 22, 24 However, some studies have found no correlation between discontinuation and CD4 levels, 17, 25 while others even found a positive relation with higher CD4 levels. 7,13 Suboptimal adherence is a well-known driver of therapeutic failure.
14 The suboptimal regimens administered during the pre-HAART and early HAART eras, in terms of toxicity/ intolerance and pill burden, 19 can account for the high rate of discontinuation found at the earlier timepoints analysed. Previous studies have reported that women are more likely to discontinue than men.
7,21,23 Treatment discontinuation in women has been related to higher relative hazards of initial HAART change because of intolerance and/or toxicity and poorer adherence. 26, 27 Also, female gender, drug injection use and aboriginal ethnicity show some degree of interconnection within British Columbia. 28 In addition, other studies have shown that women are less likely to receive ART, tend to initiate treatment at a later stage of disease and suffer more social problems affecting their adherence when compared with men. 26, 29, 30 Furthermore, the higher rate of discontinuation observed in women in our study could be partially explained by the fact that pregnant women were not excluded from the study population. However, when these women were excluded from the analysis, the results were unchanged. It may also be related to the fact that women are more likely to be injection drug users and to be aboriginal. Other social-structural factors, such as housing, income, education and stigma, may disproportionally affect women. These considerations suggest that gender-specific initiatives need to be broadened in order to reduce treatment discontinuation rates among HIV-positive women.
Focusing on the most recent calendar period in our study (2006 -10) , female gender, low ART adherence and younger age were still related in the adjusted analysis. In addition, during this period, ADIs at baseline and all initial therapies other than two NRTIs + NNRTI were associated with discontinuation. Previous studies reported that patients with ADIs are more likely to discontinue because of drug-related side effects. 17 The link to PI-containing regimens found here may be explained by the poor tolerability of PI-based regimens due to a number of associated adverse side effects. 31 -33 However, regimen-related discontinuation should be considered carefully because other confounding factors influence this result.
Readers should be cautious when interpreting our results. We do not consistently have data describing the reason for switching or stopping a regimen. Nevertheless, to analyse this matter we inferred the possible reason for discontinuation based on the viral load, suppressed or not, at the time of discontinuation. In agreement with studies cited previously, we found that discontinuations due to virological failure decreased over time while discontinuations due to tolerability issues increased, probably driven by simplification strategies. Ethnicity, risk status and HCV variables were excluded from the analysis due to missing values. The percentages of injection drug users (44.7%) and HCV/ HIV-coinfected patients (45.3%) present in our study were relatively high and could have influenced the overall rate of discontinuation. However, when these variables were included in the model none was related to discontinuation in the adjusted analysis (data not shown). In addition, our measure of adherence was based on prescription refill records and did not directly measure the number of pills that were actually taken. However, estimates of adherence based on prescription refill compliance Number at risk  37  9  3  3  2  1  1 34  1110  820  668  522  398  315  174 566  911  697  596  463  370  267  113 379  49  24  20  16  12  7  2 Temporal trends in the discontinuation of first-line antiretroviral therapy 2207 JAC have been independently associated with clinical and biological endpoints. 34 Nonetheless, we can assume relatively good adherence in our cohort based on recent studies analysing adherence to ART in British Columbia. 22 Our cohort consists of individuals who access a universal, publicly funded healthcare system where medically necessary services, including HAART, are provided free of charge. Consequently, even the most marginalized participants in our cohort were within the reach of medical and social services and were deemed adequately prepared to adhere to their treatment regimen. Accordingly, the universal nature of the Canadian healthcare system gave us the opportunity to explore discontinuation rates without the biases introduced by access to care directly related to income or health insurance coverage.
In conclusion, although we have shown that the rates of discontinuation to first-line therapy are decreasing over time, the probability of discontinuing the first-line regimen is still high even for the latest treatment era and drug combinations and may be related to social-structural barriers not measured here. Focusing on the most recent era, younger women on PI regimens and those not achieving optimal adherence run the risk of discontinuing first-line ART and should be closely monitored and provided with support. Gonzalez-Serna et al.
